DNMT3A and acute myeloid leukemia: In addition, the mutation of DNMT3A was found to correlate with a low CR rate in AML patients with an intermediate-risk profile, indicating that the mutation of DNMT3A represents a novel prognostic index for intermediate-risk AML patients.